EP Wealth Advisors LLC Makes New $236,000 Investment in Progyny, Inc. $PGNY

EP Wealth Advisors LLC purchased a new position in Progyny, Inc. (NASDAQ:PGNY) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 10,550 shares of the company’s stock, valued at approximately $236,000.

Other institutional investors also recently modified their holdings of the company. D. E. Shaw & Co. Inc. bought a new stake in Progyny in the 4th quarter worth about $11,265,000. Nuveen LLC purchased a new position in shares of Progyny during the first quarter valued at approximately $13,645,000. Voloridge Investment Management LLC lifted its position in Progyny by 85.5% during the fourth quarter. Voloridge Investment Management LLC now owns 1,197,993 shares of the company’s stock valued at $20,665,000 after purchasing an additional 552,066 shares during the period. CenterBook Partners LP boosted its holdings in Progyny by 458.2% in the first quarter. CenterBook Partners LP now owns 515,626 shares of the company’s stock worth $11,519,000 after purchasing an additional 423,257 shares during the last quarter. Finally, Deutsche Bank AG grew its position in Progyny by 533.2% in the 4th quarter. Deutsche Bank AG now owns 376,357 shares of the company’s stock worth $6,492,000 after purchasing an additional 316,918 shares during the period. 94.93% of the stock is owned by hedge funds and other institutional investors.

Progyny Stock Performance

Shares of PGNY stock opened at $22.97 on Wednesday. The stock has a fifty day simple moving average of $22.97 and a two-hundred day simple moving average of $22.22. The firm has a market capitalization of $1.98 billion, a PE ratio of 38.93, a PEG ratio of 1.87 and a beta of 1.33. Progyny, Inc. has a 52-week low of $13.39 and a 52-week high of $26.76.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.19 EPS for the quarter, missing the consensus estimate of $0.42 by ($0.23). The business had revenue of $332.87 million during the quarter, compared to analysts’ expectations of $315.70 million. Progyny had a net margin of 4.28% and a return on equity of 10.69%. Progyny’s revenue was up 9.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.17 earnings per share. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. On average, sell-side analysts forecast that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on the company. Leerink Partnrs raised Progyny from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 8th. Wall Street Zen raised shares of Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. JPMorgan Chase & Co. raised their price objective on shares of Progyny from $23.00 to $25.00 and gave the stock a “neutral” rating in a report on Tuesday, August 26th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $28.00 target price (up from $26.00) on shares of Progyny in a report on Friday, August 8th. Finally, Truist Financial lifted their price target on shares of Progyny from $24.00 to $27.00 and gave the stock a “hold” rating in a research note on Thursday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $25.30.

Insider Activity at Progyny

In other Progyny news, Director Kevin K. Gordon sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $22.04, for a total value of $55,100.00. Following the completion of the transaction, the director directly owned 12,501 shares in the company, valued at $275,522.04. This represents a 16.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Allison Swartz sold 2,398 shares of Progyny stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $22.96, for a total transaction of $55,058.08. Following the sale, the executive vice president owned 79,697 shares in the company, valued at approximately $1,829,843.12. The trade was a 2.92% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 7,895 shares of company stock valued at $179,311 over the last 90 days. 9.40% of the stock is currently owned by corporate insiders.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.